Key Points
- X4 Pharmaceuticals CFO David Kirske sold 11,767 shares at an average price of $2.86, generating $33,653.62 and reducing his direct ownership by 7.01% to 155,983 shares.
- XFOR shares opened at $2.90 and remain near their 52-week low of $2.73. The company reported a quarterly loss of $0.13 per share but exceeded revenue expectations, posting $8.81 million versus the $2.42 million consensus estimate.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $11.25, while institutional investors own 72.03% of the stock. X4’s primary product, FDA-approved XOLREMDI, targets WHIM syndrome.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CFO David Kirske sold 11,767 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total transaction of $33,653.62. Following the completion of the sale, the chief financial officer directly owned 155,983 shares of the company's stock, valued at approximately $446,111.38. This trade represents a 7.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
X4 Pharmaceuticals Stock Up 2.5%
Shares of XFOR opened at $2.90 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30. The company has a 50-day simple moving average of $3.79 and a 200-day simple moving average of $3.97. X4 Pharmaceuticals, Inc. has a 52 week low of $2.73 and a 52 week high of $4.83. The firm has a market capitalization of $287.53 million, a P/E ratio of -2.42 and a beta of 0.46.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. On average, equities research analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently commented on XFOR shares. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an "overweight" rating and a $11.00 target price for the company. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.25.
Check Out Our Latest Stock Analysis on XFOR
Hedge Funds Weigh In On X4 Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. Empery Asset Management LP acquired a new position in X4 Pharmaceuticals during the fourth quarter worth $35,804,000. Perceptive Advisors LLC acquired a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $25,258,000. Bank of New York Mellon Corp bought a new stake in shares of X4 Pharmaceuticals in the 2nd quarter worth about $917,000. Bank of America Corp DE grew its holdings in shares of X4 Pharmaceuticals by 321.3% in the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company's stock worth $622,000 after purchasing an additional 114,915 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of X4 Pharmaceuticals in the 2nd quarter worth about $313,000. Institutional investors own 72.03% of the company's stock.
About X4 Pharmaceuticals
(
Get Free Report)
X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company's research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.
X4's primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
